BR9707589A - Proteìna hìbrida, molécula de dna, vetor de expressão, célula hospedeira, composição farmacêutica e processos para produzir proteìna hìbrida e para induzir maturação folicular. - Google Patents

Proteìna hìbrida, molécula de dna, vetor de expressão, célula hospedeira, composição farmacêutica e processos para produzir proteìna hìbrida e para induzir maturação folicular.

Info

Publication number
BR9707589A
BR9707589A BR9707589-2A BR9707589A BR9707589A BR 9707589 A BR9707589 A BR 9707589A BR 9707589 A BR9707589 A BR 9707589A BR 9707589 A BR9707589 A BR 9707589A
Authority
BR
Brazil
Prior art keywords
hybrid protein
processes
pharmaceutical composition
expression vector
dna molecule
Prior art date
Application number
BR9707589-2A
Other languages
English (en)
Inventor
Robert K Campbell
Bradford A Jameson
Scott C Chappel
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of BR9707589A publication Critical patent/BR9707589A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/04Preparation of compounds containing amino groups bound to a carbon skeleton by substitution of functional groups by amino groups
    • C07C209/22Preparation of compounds containing amino groups bound to a carbon skeleton by substitution of functional groups by amino groups by substitution of other functional groups
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/24Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/59Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

"PROTEìNA HìBRIDA, MOLéCULA DE DNA, VETOR DE EXPRESSãO, CéLULA HOSPEDEIRA, COMPOSIçãO FARMACêUTICA E PROCESSOS PARA PRODUZIR PROTEìNA HìBRIDA E PARA INDUZIR MATURAçãO FOLICULAR". Uma proteína híbrida inclui duas sequências de aminoácido co-expressas formando um dímero. Cada sequência contém a porção de ligação de um receptor, como TBP1, ou TBP2, ou um ligando, como IL-6, IFN-<225> E TPO, ligado a uma subunidade de um hormónio proteináceo heterodimérico, como hCG. Cada sequência coexpressa contém uma subunidade de hormónio correspondente de modo a formar um heterodímero quando da expresão. As moléculas de DNA correspondentes, vetores de expressão e céluas hospedeiras são tambémn descritos como são as composições farmacêutcas, e um processo para produzir estas proteínas.
BR9707589-2A 1996-02-20 1997-02-20 Proteìna hìbrida, molécula de dna, vetor de expressão, célula hospedeira, composição farmacêutica e processos para produzir proteìna hìbrida e para induzir maturação folicular. BR9707589A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1193696P 1996-02-20 1996-02-20
PCT/US1997/002315 WO1997030161A1 (en) 1996-02-20 1997-02-20 Hybrid proteins which form heterodimers

Publications (1)

Publication Number Publication Date
BR9707589A true BR9707589A (pt) 2000-01-04

Family

ID=21752599

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9707589-2A BR9707589A (pt) 1996-02-20 1997-02-20 Proteìna hìbrida, molécula de dna, vetor de expressão, célula hospedeira, composição farmacêutica e processos para produzir proteìna hìbrida e para induzir maturação folicular.

Country Status (25)

Country Link
US (5) US6193972B1 (pt)
EP (1) EP0894141B1 (pt)
JP (2) JP4140927B2 (pt)
KR (1) KR100369985B1 (pt)
CN (1) CN1261579C (pt)
AT (1) ATE295887T1 (pt)
AU (1) AU706504B2 (pt)
BG (1) BG64510B1 (pt)
BR (1) BR9707589A (pt)
CA (1) CA2245877C (pt)
CZ (1) CZ291212B6 (pt)
DE (1) DE69733309T2 (pt)
DK (1) DK0894141T3 (pt)
EA (1) EA002474B1 (pt)
EE (1) EE04025B1 (pt)
ES (1) ES2241040T3 (pt)
HU (1) HUP9900619A3 (pt)
IL (1) IL125864A (pt)
NO (1) NO321777B1 (pt)
NZ (1) NZ331539A (pt)
PL (1) PL187400B1 (pt)
PT (1) PT894141E (pt)
SK (1) SK282326B6 (pt)
UA (1) UA52646C2 (pt)
WO (1) WO1997030161A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ331539A (en) * 1996-02-20 2000-01-28 Applied Research Systems Hybrid proteins from two coexpressed receptors to form a heterodimer
US6635740B1 (en) * 1997-03-27 2003-10-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Ligand/lytic peptide compositions and methods of use
CA2301846A1 (en) 1997-09-04 1999-03-11 Gryphon Sciences Modular protein libraries and methods of preparation
EA006605B1 (ru) * 2000-02-22 2006-02-24 Апплайд Резеч Системз Арс Холдинг Н.В. СПОСОБ ОЧИСТКИ РЕКОМБИНАНТНОГО чХГ
US20030228600A1 (en) * 2000-07-14 2003-12-11 Eppendorf 5 Prime, Inc. DNA isolation method and kit
IL147414A0 (en) * 2001-12-31 2002-08-14 Yeda Res & Dev Ifnar2 mutants, their production and use
US20030157091A1 (en) * 2002-02-14 2003-08-21 Dyax Corporation Multi-functional proteins
DE10247755B4 (de) * 2002-10-14 2006-01-19 Pfizenmaier, Klaus, Prof. Dr. Selektive, lokale Aktivierung von Mitgliedern der TNF-Rezeptorfamilie durch systemisch inaktive nicht-Antikörper-TNF-Liganden-Fusionsproteine
AU2005207960A1 (en) * 2004-01-28 2005-08-11 Syntonix Pharmaceuticals, Inc. Heterodimeric follicle stimulating hormone-Fc (FSH-Fc) fusion proteins for the treatment of infertility
JP2008525002A (ja) 2004-12-23 2008-07-17 ラボラトワール セローノ ソシエテ アノニム Bcmaポリペプチド及びその使用
PT1885753E (pt) 2005-06-03 2011-10-06 Ares Trading Sa Produção de proteína recombinante de ligação a il-18
CN108129573B (zh) * 2007-09-21 2021-10-08 加利福尼亚大学董事会 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性
EP3009513A1 (en) * 2008-02-01 2016-04-20 Chromocell Corporation Novel cell lines and methods
CN102002495B (zh) * 2009-08-31 2012-07-18 成都蓉生药业有限责任公司 用于表达异二聚体糖蛋白激素的表达框、表达载体及制备方法
SG10201602371VA (en) * 2011-03-25 2016-04-28 Glenmark Pharmaceuticals Sa Hetero-dimeric immunoglobulins
ES2771478T3 (es) 2013-02-18 2020-07-06 Vegenics Pty Ltd Moléculas de unión a ligando y usos de las mismas
JP7439372B2 (ja) * 2018-06-21 2024-02-28 シャタック ラボ,インコーポレイテッド ヘテロ二量体タンパク質及びその使用
US20220227837A1 (en) * 2019-05-24 2022-07-21 Proviva Therapeutics (Hong Kong) Limited Il-2 compositions and methods of use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0721983A1 (en) * 1988-01-22 1996-07-17 ZymoGenetics, Inc. Methods of producing biologically active peptide dimers
US5705478A (en) * 1989-02-21 1998-01-06 Washington University Covalently linked β subunits of the glycoprotein hormones as antagonists
US6225449B1 (en) * 1991-10-04 2001-05-01 Washington University Hormone analogs with multiple CTP extensions
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
AU5355790A (en) * 1989-04-19 1990-11-16 Cetus Corporation Multifunctional m-csf proteins and genes encoding therefor
US5650150A (en) * 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
IL99120A0 (en) * 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
US5932448A (en) * 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
ATE242322T1 (de) 1992-03-30 2003-06-15 Immunex Corp Fusionsprotein , das zwei rezeptoren des tumornekrose-faktors enthält
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
IL111125A0 (en) 1994-05-11 1994-12-29 Yeda Res & Dev Soluble oligomeric tnf/ngf super family ligand receptors and their use
NZ331539A (en) * 1996-02-20 2000-01-28 Applied Research Systems Hybrid proteins from two coexpressed receptors to form a heterodimer
US6194177B1 (en) * 1996-02-20 2001-02-27 Applied Research Systems Ars Holding N.V. DNA encoding a hybrid heterodimeric protein

Also Published As

Publication number Publication date
CZ291212B6 (cs) 2003-01-15
UA52646C2 (uk) 2003-01-15
DE69733309T2 (de) 2006-01-19
US20040230034A1 (en) 2004-11-18
NO321777B1 (no) 2006-07-03
SK282326B6 (sk) 2002-01-07
SK114898A3 (en) 1999-07-12
CA2245877A1 (en) 1997-08-21
US7291339B2 (en) 2007-11-06
US20010014333A1 (en) 2001-08-16
CN1212017A (zh) 1999-03-24
DE69733309D1 (de) 2005-06-23
CZ264498A3 (cs) 1998-12-16
KR100369985B1 (ko) 2004-03-26
WO1997030161A1 (en) 1997-08-21
EA002474B1 (ru) 2002-06-27
CA2245877C (en) 2013-09-03
AU2125297A (en) 1997-09-02
EA199800744A1 (ru) 1999-02-25
BG64510B1 (bg) 2005-05-31
EE04025B1 (et) 2003-04-15
EP0894141A1 (en) 1999-02-03
PT894141E (pt) 2005-09-30
ATE295887T1 (de) 2005-06-15
DK0894141T3 (da) 2005-08-22
EP0894141B1 (en) 2005-05-18
US20100075402A1 (en) 2010-03-25
HUP9900619A3 (en) 2001-11-28
AU706504B2 (en) 1999-06-17
US6193972B1 (en) 2001-02-27
PL187400B1 (pl) 2004-06-30
CN1261579C (zh) 2006-06-28
NO983799L (no) 1998-10-19
US20090240039A1 (en) 2009-09-24
HUP9900619A2 (hu) 1999-06-28
EE9800256A (et) 1999-02-15
NZ331539A (en) 2000-01-28
IL125864A0 (en) 1999-04-11
JP4140927B2 (ja) 2008-08-27
JP2008019258A (ja) 2008-01-31
IL125864A (en) 2007-07-04
US6663867B2 (en) 2003-12-16
BG102705A (en) 1999-04-30
KR19990082482A (ko) 1999-11-25
PL328454A1 (en) 1999-02-01
ES2241040T3 (es) 2005-10-16
NO983799D0 (no) 1998-08-19
JP2000504586A (ja) 2000-04-18

Similar Documents

Publication Publication Date Title
BR9707589A (pt) Proteìna hìbrida, molécula de dna, vetor de expressão, célula hospedeira, composição farmacêutica e processos para produzir proteìna hìbrida e para induzir maturação folicular.
Sonenberg ATP/Mg++-dependent cross-linking of cap binding proteins to the 5′ end of eukaryotic mRNA
AR024699A1 (es) Polipeptidos hibridos con propiedades farmacocineticas aumentadas
DE69630708D1 (de) An den erythropoietin-rezeptor bindende zusammensetzungen und peptide
BRPI0516011A (pt) moléculas fc modificadas
CA2288600A1 (en) A method for making multispecific antibodies having heteromultimeric and common components
DE69535587D1 (de) Rekombinantes allergen, seine fragmente und die damit korrespondierenden dna-moleküle, vektoren, und diese dna-moleküle enthaltenden wirte, und dignostische und therapeutische verwendungen besagter allergene und fragmente
ES549185A0 (es) Procedimiento para sintetizar peptidos a partir de aminoaci-dos
Cole et al. Disulfide bond structure and N-glycosylation sites of the extracellular domain of the human interleukin-6 receptor
Weiss et al. Covalent HLA-B27/peptide complex induced by specific recognition of an aziridine mimic of arginine.
Akhmedov et al. Theoretical conformational analysis of brain peptides: β‐Melanocyte‐stimulating hormone
Friedman et al. Reactions of proteins with ethyl vinyl sulfone
EP1557432A3 (en) Hybrid proteins which form heterodimers
Pratesi et al. Synthesis of dicarba-cyclooctapeptide Somatostatin analogs by conventional and MW-assisted RCM: A study about the impact of the configuration at Cα of selected amino acids
Liu et al. Strategies for the synthesis of fluorescently labelled PNA
US20050096456A1 (en) Compounds comprising pseudo-amino acids
Ramachandran et al. Strategies for the Analysis of the Structure and Function of Cell Surface Receptors
SE9704162D0 (sv) Chronic lymphocytic leukemia nucleotides and proteins
MX9603859A (es) Producto y proceso para la regulacion de celulas t.

Legal Events

Date Code Title Description
TE Change of address
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B25A Requested transfer of rights approved

Owner name: LABORATOIRES SERONO S.A. (CH)

Free format text: TRANSFERIDO DE: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.